Insights into the Associative Role of Hypertension and Angiotensin II Receptor in Lower Urinary Tract Dysfunction

Overview

Journal Hypertens Res

Specialty Cardiology & Vascular Diseases

Date 2024 Feb 13

PMID 38351189

Authors

Shogo Shimizu

Affiliations

Soon will be listed here.

Abstract

In men, the lower urinary tract comprises the urinary bladder, urethra, and prostate, and its primary functions include urine storage and voiding. Hypertension is a condition that causes multi-organ damage and an age-dependent condition. Hypertension and the renin-angiotensin system activation are associated with the development of lower urinary tract dysfunction. Hypertensive animal models show bladder dysfunction, urethral dysfunction, and prostatic hyperplasia. In the renin-angiotensin system, angiotensin II and the angiotensin II type 1 receptor, which are expressed in the lower urinary tract, have been implicated in the pathogenesis of lower urinary tract dysfunction. Moreover, among the several antihypertensives, renin-angiotensin system inhibitors have proven effective in human and animal models of lower urinary tract dysfunction. This review aimed to elucidate the hitherto known mechanisms underlying the development of lower urinary tract dysfunction in relation to hypertension and the angiotensin II/angiotensin II type 1 receptor axis and the effect of renin-angiotensin system inhibitors on lower urinary tract dysfunction. Possible mechanisms through which hypertension or activation of Ang II/AT1 receptor axis causes LUTD such as bladder dysfunction, urethral dysfunction, and prostatic hyperplasia. LUT: lower urinary tract, LUTD: lower urinary tract dysfunction, AT1: angiotensin II type 1, ACE: angiotensin-converting enzyme.

Citing Articles

Role of local angiotensin II signaling in bladder function.

Anderson H, Robilotto G, Mickle A Am J Physiol Renal Physiol. 2024; 327(5):F726-F738.

PMID: 39265080 PMC: 11563647. DOI: 10.1152/ajprenal.00204.2024.

Association of detrusor underactivity with aging and metabolic syndrome: suggestions from animal models.

Shimizu S J Smooth Muscle Res. 2024; 60:23-30.

PMID: 39085088 PMC: 11291108. DOI: 10.1540/jsmr.60.23.

References

de Groat W, Griffiths D, Yoshimura N . Neural control of the lower urinary tract. Compr Physiol. 2015; 5(1):327-96. PMC: 4480926. DOI: 10.1002/cphy.c130056. View

Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y . The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019; 42(9):1235-1481. DOI: 10.1038/s41440-019-0284-9. View

Sugaya K, Kadekawa K, Ikehara A, Nakayama T, Gakiya M, Nashiro F . Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia. Int J Urol. 2003; 10(11):569-74. DOI: 10.1046/j.1442-2042.2003.00707.x. View

Ponholzer A, Temml C, Wehrberger C, Marszalek M, Madersbacher S . The association between vascular risk factors and lower urinary tract symptoms in both sexes. Eur Urol. 2006; 50(3):581-6. DOI: 10.1016/j.eururo.2006.01.031. View

Ohishi M, Kubozono T, Higuchi K, Akasaki Y . Hypertension, cardiovascular disease, and nocturia: a systematic review of the pathophysiological mechanisms. Hypertens Res. 2021; 44(7):733-739. DOI: 10.1038/s41440-021-00634-0. View

Ocaranza M, Riquelme J, Garcia L, Jalil J, Chiong M, Santos R . Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol. 2019; 17(2):116-129. PMC: 7097090. DOI: 10.1038/s41569-019-0244-8. View

Ghatage T, Goyal S, Dhar A, Bhat A . Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies. Hypertens Res. 2021; 44(7):740-755. PMC: 7967108. DOI: 10.1038/s41440-021-00643-z. View

Takahashi K, Tanaka T, Yoshizawa Y, Fujisaki-Sueda-Sakai M, Son B, Iijima K . Lower urinary tract symptoms and functional ability in older adults: a community-based cross-sectional study. BMJ Open. 2022; 12(4):e054530. PMC: 9039374. DOI: 10.1136/bmjopen-2021-054530. View

Irwin D, Kopp Z, Agatep B, Milsom I, Abrams P . Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011; 108(7):1132-8. DOI: 10.1111/j.1464-410X.2010.09993.x. View

10.

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U . The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002; 21(2):167-78. DOI: 10.1002/nau.10052. View

11.

Peyronnet B, Mironska E, Chapple C, Cardozo L, Oelke M, Dmochowski R . A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment. Eur Urol. 2019; 75(6):988-1000. DOI: 10.1016/j.eururo.2019.02.038. View

12.

Madersbacher S, Sampson N, Culig Z . Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. Gerontology. 2019; 65(5):458-464. DOI: 10.1159/000496289. View

13.

Arnold M, Gaillardetz A, Ohiokpehai J . Benign Prostatic Hyperplasia: Rapid Evidence Review. Am Fam Physician. 2023; 107(6):613-622. View

14.

Wu Y, Chueh K, Chuang S, Long C, Lu J, Juan Y . Bladder Hyperactivity Induced by Oxidative Stress and Bladder Ischemia: A Review of Treatment Strategies with Antioxidants. Int J Mol Sci. 2021; 22(11). PMC: 8199707. DOI: 10.3390/ijms22116014. View

15.

Tarcan T, Choi H, Azadzoi K . Molecular Regulation of Concomitant Lower Urinary Tract Symptoms and Erectile Dysfunction in Pelvic Ischemia. Int J Mol Sci. 2022; 23(24). PMC: 9782153. DOI: 10.3390/ijms232415988. View

16.

Shimizu S, Tsounapi P, Shimizu T, Honda M, Inoue K, Dimitriadis F . Lower urinary tract symptoms, benign prostatic hyperplasia/benign prostatic enlargement and erectile dysfunction: are these conditions related to vascular dysfunction?. Int J Urol. 2014; 21(9):856-64. DOI: 10.1111/iju.12501. View

17.

Saito M, Tsounapi P, Oikawa R, Shimizu S, Honda M, Sejima T . Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH. Sci Rep. 2014; 4:3822. PMC: 3897960. DOI: 10.1038/srep03822. View

18.

Akbar A, Liu K, Michos E, Bancks M, Brubaker L, Markossian T . Association of Overactive Bladder With Hypertension and Blood Pressure Control: The Multi-Ethnic Study of Atherosclerosis (MESA). Am J Hypertens. 2021; 35(1):22-30. PMC: 8730485. DOI: 10.1093/ajh/hpaa186. View

19.

Yokoyama O, Nishizawa O, Homma Y, Takeda M, Gotoh M, Kakizaki H . Nocturnal Polyuria and Hypertension in Patients with Lifestyle Related Diseases and Overactive Bladder. J Urol. 2016; 197(2):423-431. DOI: 10.1016/j.juro.2016.08.087. View

20.

Sugaya K, Nishijima S, Oda M, Owan T, Miyazato M, Ogawa Y . Biochemical and body composition analysis of nocturia in the elderly. Neurourol Urodyn. 2007; 27(3):205-11. DOI: 10.1002/nau.20492. View